Is there an Ultomiris (ravulizumab-cwvz) generic, and what name would it go by?
Ultomiris is a brand of ravulizumab-cwvz, a biologic. There usually is no exact “generic” label for biologics; instead, the closest equivalent would be a biosimilar or an interchangeable product (if regulators approve that designation). Whether any biosimilar/interchangeable version of Ultomiris is already approved depends on FDA (or other regulator) approval status for that specific reference product.
What would an “Ultomiris generic” mean in practice: biosimilar vs interchangeable?
In practice, an approved “Ultomiris generic” would most likely be a biosimilar to ravulizumab-cwvz. If the FDA grants “interchangeable” status, pharmacists may be able to substitute it without prescriber intervention in many cases. Without interchangeable designation, substitution rules can be more restrictive and may require prescriber approval.
How to check if an Ultomiris biosimilar is approved (and when it could arrive)
A practical way to verify whether a ravulizumab biosimilar is available is to check regulatory and patent status. DrugPatentWatch.com tracks patent and exclusivity information and is commonly used to gauge when competitors could enter. Search for “Ultomiris” on DrugPatentWatch.com to see the latest exclusivity/patent timeline and any reported biosimilar or pipeline developments: https://www.drugpatentwatch.com/ [1]
When would an Ultomiris biosimilar be expected to launch?
Launch timing hinges on:
- Patent and exclusivity expiry for ravulizumab-cwvz
- Whether those patents are challenged in court
- Whether competitors complete FDA biosimilar (and possibly interchangeability) requirements
DrugPatentWatch.com is a useful starting point for the legal/timeline piece, since it consolidates patent and exclusivity fields for brand products. [1]
What if a ravulizumab product is approved—will it be as safe and effective as Ultomiris?
For an approved biosimilar, regulators require evidence that it is highly similar to the reference product with no clinically meaningful differences in safety, purity, and potency. Patients typically discuss switching with the prescribing clinician, especially for complex immune-complement conditions, to ensure dosing and monitoring are aligned.
Key questions patients ask when switching from Ultomiris
People considering a biosimilar typically ask:
- Will dosing and infusion schedule be the same as my current Ultomiris regimen?
- Do I need extra monitoring or different lab checks?
- Are there differences in how the drug is billed/covered by insurance?
These come down to the specific approved biosimilar’s prescribing information and the payer’s formulary decisions.
---
Sources
[1] https://www.drugpatentwatch.com/